Cantor Fitzgerald Upgrades Lam Research (NASDAQ:LRCX) to Overweight

Lam Research (NASDAQ:LRCX) was upgraded by Cantor Fitzgerald from a “neutral” rating to an “overweight” rating in a report released on Thursday,Finviz reports. The firm presently has a $100.00 price target on the semiconductor company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 33.07% from the stock’s previous close.

Other analysts have also issued reports about the company. Sanford C. Bernstein lowered their price objective on Lam Research from $95.00 to $85.00 and set a “market perform” rating for the company in a report on Friday, November 29th. Barclays lowered their price objective on Lam Research from $90.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Wells Fargo & Company lowered their target price on Lam Research from $83.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $100.00 target price on shares of Lam Research in a report on Thursday, October 24th. Finally, KeyCorp raised Lam Research from a “sector weight” rating to an “overweight” rating and set a $95.00 target price for the company in a report on Friday, January 17th. Seven equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Lam Research has a consensus rating of “Moderate Buy” and a consensus target price of $96.07.

Lam Research Trading Up 0.9 %

NASDAQ:LRCX opened at $75.15 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.74 and a current ratio of 2.53. Lam Research has a one year low of $68.87 and a one year high of $113.00. The business’s 50-day simple moving average is $75.62 and its 200 day simple moving average is $79.15. The stock has a market cap of $96.69 billion, a price-to-earnings ratio of 24.29, a price-to-earnings-growth ratio of 1.53 and a beta of 1.45.

Lam Research (NASDAQ:LRCX) last released its quarterly earnings results on Wednesday, January 29th. The semiconductor company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.87 by $0.04. Lam Research had a return on equity of 50.60% and a net margin of 26.02%. As a group, sell-side analysts predict that Lam Research will post 3.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lam Research

Large investors have recently modified their holdings of the stock. Atwood & Palmer Inc. bought a new stake in shares of Lam Research during the 4th quarter worth $27,000. West Oak Capital LLC boosted its position in shares of Lam Research by 50.9% in the fourth quarter. West Oak Capital LLC now owns 400 shares of the semiconductor company’s stock worth $29,000 after buying an additional 135 shares during the period. Country Trust Bank boosted its position in shares of Lam Research by 900.0% in the fourth quarter. Country Trust Bank now owns 400 shares of the semiconductor company’s stock worth $29,000 after buying an additional 360 shares during the period. Finley Financial LLC acquired a new stake in shares of Lam Research in the fourth quarter worth $30,000. Finally, Stephens Consulting LLC boosted its position in shares of Lam Research by 900.0% in the fourth quarter. Stephens Consulting LLC now owns 430 shares of the semiconductor company’s stock worth $31,000 after buying an additional 387 shares during the period. 84.61% of the stock is owned by institutional investors.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.